Home The Word Brain	My Amedeo FAQ Privacy About
	2049 Chinese The 20K Word Road to Mandarin Proficiency By B. S. Kamps et al.

Lung Cancer

Free Subscription Articles published in Nat Med Retrieve available abstracts of 30 articles: HTML format

Single Articles

February 2024
1. BESSE B, Pons-Tostivint E, Park K, Hartl S, et al
   Biomarker-directed targeted therapy plus durvalumab in advanced non-small-cell lung cancer: a phase 2 umbrella trial.
   Nat Med. 2024 Feb 13. doi: 10.1038/s41591-024-02808.
   PubMed     Abstract available
   
   
   October 2023
2. DEUTSCH JS, Cimino-Mathews A, Thompson E, Provencio M, et al
   Association between pathologic response and survival after neoadjuvant therapy in lung cancer.
   Nat Med. 2023 Oct 30. doi: 10.1038/s41591-023-02660.
   PubMed     Abstract available
   
   
   
3. CHAFT JE, Oezkan F, Kris MG, Bunn PA, et al
   Author Correction: Neoadjuvant atezolizumab for resectable non-small cell lung cancer: an open-label, single-arm phase II trial.
   Nat Med. 2023 Oct 10. doi: 10.1038/s41591-023-02627.
   PubMed    
   
   
   
4. ANAGNOSTOU V, Ho C, Nicholas G, Juergens RA, et al
   ctDNA response after pembrolizumab in non-small cell lung cancer: phase 2 adaptive trial results.
   Nat Med. 2023 Oct 9. doi: 10.1038/s41591-023-02598.
   PubMed     Abstract available
   
   
   September 2023
5. CHO BC, Kim DW, Spira AI, Gomez JE, et al
   Amivantamab plus lazertinib in osimertinib-relapsed EGFR-mutant advanced non-small cell lung cancer: a phase 1 trial.
   Nat Med. 2023 Sep 14. doi: 10.1038/s41591-023-02554.
   PubMed     Abstract available
   
   
   July 2023
6. LIU SM, Tu HY, Wei XW, Yan HH, et al
   First-line pyrotinib in advanced HER2-mutant non-small-cell lung cancer: a patient-centric phase 2 trial.
   Nat Med. 2023 Jul 24. doi: 10.1038/s41591-023-02461.
   PubMed     Abstract available
   
   
   
7. GUTIERREZ M, Lam WS, Hellmann MD, Gubens MA, et al
   Biomarker-directed, pembrolizumab-based combination therapy in non-small cell lung cancer: phase 2 KEYNOTE-495/KeyImPaCT trial interim results.
   Nat Med. 2023 Jul 10. doi: 10.1038/s41591-023-02385.
   PubMed     Abstract available
   
   
   June 2023
8. SIKKEMA L, Ramirez-Suastegui C, Strobl DC, Gillett TE, et al
   An integrated cell atlas of the lung in health and disease.
   Nat Med. 2023;29:1563-1577.
   PubMed     Abstract available
   
   
   May 2023
9. GOLDSMITH KC, Park JR, Kayser K, Malvar J, et al
   Lorlatinib with or without chemotherapy in ALK-driven refractory/relapsed neuroblastoma: phase 1 trial results.
   Nat Med. 2023;29:1092-1102.
   PubMed     Abstract available
   
   
   April 2023
10. AL-SAWAF O, Weiss J, Skrzypski M, Lam JM, et al
    Body composition and lung cancer-associated cachexia in TRACERx.
    Nat Med. 2023 Apr 12. doi: 10.1038/s41591-023-02232.
    PubMed     Abstract available
    
    
    
11. 
    High-resolution circulating tumor DNA testing predicts survival in metastatic lung cancer clinical trials.
    Nat Med. 2023;29:797-798.
    PubMed    
    
    
    
12. 
    Clinicogenomic landscape of morphological evolution in lung adenocarcinoma.
    Nat Med. 2023;29:795-796.
    PubMed    
    
    
    
13. KARASAKI T, Moore DA, Veeriah S, Naceur-Lombardelli C, et al
    Evolutionary characterization of lung adenocarcinoma morphology in TRACERx.
    Nat Med. 2023;29:833-845.
    PubMed     Abstract available
    
    
    
14. GLITZA OLIVA IC, Ferguson SD, Bassett R Jr, Foster AP, et al
    Concurrent intrathecal and intravenous nivolumab in leptomeningeal disease: phase 1 trial interim results.
    Nat Med. 2023;29:898-905.
    PubMed     Abstract available
    
    
    March 2023
15. CONROY M, Forde PM
    Advancing neoadjuvant immunotherapy for lung cancer.
    Nat Med. 2023 Mar 16. doi: 10.1038/s41591-023-02246.
    PubMed    
    
    
    
16. CASCONE T, Leung CH, Weissferdt A, Pataer A, et al
    Neoadjuvant chemotherapy plus nivolumab with or without ipilimumab in operable non-small cell lung cancer: the phase 2 platform NEOSTAR trial.
    Nat Med. 2023 Mar 16. doi: 10.1038/s41591-022-02189.
    PubMed     Abstract available
    
    
    
17. ASSAF ZJF, Zou W, Fine AD, Socinski MA, et al
    A longitudinal circulating tumor DNA-based model associated with survival in metastatic non-small-cell lung cancer.
    Nat Med. 2023 Mar 16. doi: 10.1038/s41591-023-02226.
    PubMed     Abstract available
    
    
    February 2023
18. NIKNAFS N, Balan A, Cherry C, Hummelink K, et al
    Persistent mutation burden drives sustained anti-tumor immune responses.
    Nat Med. 2023;29:440-449.
    PubMed     Abstract available
    
    
    November 2022
19. JEE J, Lebow ES, Yeh R, Das JP, et al
    Overall survival with circulating tumor DNA-guided therapy in advanced non-small-cell lung cancer.
    Nat Med. 2022;28:2353-2363.
    PubMed     Abstract available
    
    
    October 2022
20. BAJAJ SS, Pan M, Potter AL, Yang CJ, et al
    Cigarette package labels to promote lung cancer screening.
    Nat Med. 2022 Oct 13. pii: 10.1038/s41591-022-02042.
    PubMed    
    
    
    September 2022
21. CHAFT JE, Oezkan F, Kris MG, Bunn PA, et al
    Neoadjuvant atezolizumab for resectable non-small cell lung cancer: an open-label, single-arm phase II trial.
    Nat Med. 2022 Sep 12. pii: 10.1038/s41591-022-01962.
    PubMed     Abstract available
    
    
    
22. PETERS S, Dziadziuszko R, Morabito A, Felip E, et al
    Atezolizumab versus chemotherapy in advanced or metastatic NSCLC with high blood-based tumor mutational burden: primary analysis of BFAST cohort C randomized phase 3 trial.
    Nat Med. 2022;28:1831-1839.
    PubMed     Abstract available
    
    
    August 2022
23. GOGISHVILI M, Melkadze T, Makharadze T, Giorgadze D, et al
    Cemiplimab plus chemotherapy versus chemotherapy alone in non-small cell lung cancer: a randomized, controlled, double-blind phase 3 trial.
    Nat Med. 2022 Aug 25. pii: 10.1038/s41591-022-01977.
    PubMed     Abstract available
    
    
    April 2022
24. O'LEARY K
    New treatment option for early-stage lung cancer.
    Nat Med. 2022 Apr 25. pii: 10.1038/d41591-022-00055.
    PubMed    
    
    
    
25. KIM ES, Velcheti V, Mekhail T, Yun C, et al
    Blood-based tumor mutational burden as a biomarker for atezolizumab in non-small cell lung cancer: the phase 2 B-F1RST trial.
    Nat Med. 2022 Apr 14. pii: 10.1038/s41591-022-01754.
    PubMed     Abstract available
    
    
    February 2022
26. DEROSA L, Routy B, Thomas AM, Iebba V, et al
    Intestinal Akkermansia muciniphila predicts clinical response to PD-1 blockade in patients with advanced non-small-cell lung cancer.
    Nat Med. 2022 Feb 3. pii: 10.1038/s41591-021-01655.
    PubMed     Abstract available
    
    
    November 2021
27. FORDE PM, Anagnostou V, Sun Z, Dahlberg SE, et al
    Durvalumab with platinum-pemetrexed for unresectable pleural mesothelioma: survival, genomic and immunologic analyses from the phase 2 PrE0505 trial.
    Nat Med. 2021;27:1910-1920.
    PubMed     Abstract available
    
    
    August 2021
28. CREELAN BC, Wang C, Teer JK, Toloza EM, et al
    Tumor-infiltrating lymphocyte treatment for anti-PD-1-resistant metastatic lung cancer: a phase 1 trial.
    Nat Med. 2021 Aug 12. pii: 10.1038/s41591-021-01462.
    PubMed     Abstract available
    
    
    
29. VEATCH JR, Simon S, Riddell SR
    Tumor-infiltrating lymphocytes make inroads in non-small-cell lung cancer.
    Nat Med. 2021 Aug 12. pii: 10.1038/s41591-021-01445.
    PubMed    
    
    
    
30. WANG M, Herbst RS, Boshoff C
    Toward personalized treatment approaches for non-small-cell lung cancer.
    Nat Med. 2021 Aug 12. pii: 10.1038/s41591-021-01450.
    PubMed     Abstract available
    
    

Thank you for your interest in scientific medicine.

AMEDEO Lung Cancer is free of charge.